Biocon Q4 Results PAT Rs 179 Crore Up 64 Percent FY26 Revenue at Rs 17270 Crore
- May 8, 2026
- Posted by: Kashish Aggarwal
- Category: News
Biocon Q4 results for FY26 announced on 7 May 2026 showed consolidated net profit before exceptional items of Rs 179 crore, up 64% year on year on an adjusted basis, while operating revenue grew 10% to Rs 4,517 crore. The Biocon Q4 EBITDA rose 29% to Rs 1,073 crore at a margin of 23%, reflecting operating leverage across the company’s integrated biosimilars and generics platform. The Biocon Q4 numbers are reported after excluding one-time generic Lenalidomide sales in Q4 FY25.
Investors tracking the Biocon Q4 results FY26 will note that the full-year FY26 net profit before exceptional items surged 323% to Rs 436 crore on revenue of Rs 16,927 crore, up 13% year on year on an adjusted basis. The Biocon Q4 results also included a landmark strategic announcement with the board approving full integration of Biocon Biologics Limited as a wholly-owned subsidiary through a share swap, creating a unified global biopharmaceutical entity. The board recommended a final dividend of Re 0.50 per share.
Get Free Stock Recommendations on Univest
Biocon Q4 FY26 Results at a Glance
| Metric | Q4 FY26 / FY26 | Change |
|---|---|---|
| Q4 Operating Revenue | Rs 4,517 crore | +10% YoY (adjusted) |
| Q4 EBITDA | Rs 1,073 crore | +29% YoY (adjusted) |
| Q4 EBITDA Margin | 23% | Expanding YoY |
| Q4 PAT (before exceptional) | Rs 179 crore | +64% YoY (adjusted) |
| FY26 Operating Revenue | Rs 16,927 crore | +13% YoY (adjusted) |
| FY26 PAT (before exceptional) | Rs 436 crore | +323% YoY (adjusted) |
| Dividend | Re 0.50 per share | FY26 final payout |
Track live financials and analyst ratings on the Univest Screener.
Key Highlights from Biocon Q4 FY26
Biosimilars Drive Growth with 26 Percent EBITDA Margin
The Biosimilars segment remained the core growth driver in the Biocon Q4 results, with Q4 operating revenue at Rs 2,756 crore up 12% YoY and EBITDA growing 33% to Rs 720 crore at a 26% margin. The Biocon Q4 biosimilars performance was supported by recent US launches including Bosaya and Aukelso, the denosumab biosimilars to Prolia and Xgeva. The segment now serves over 6.5 million patients on a moving annual basis.
Biocon Biologics Integration Unlocks Unified Strategy
The Biocon Q4 board approved the full integration of Biocon Biologics Limited as a wholly-owned subsidiary through a share swap involving up to 87.92 lakh equity shares at Rs 376.16 per share. This integration simplifies the corporate structure, unifies capital allocation, and creates a single global biopharmaceutical entity. The Biocon Q4 results mark the company’s transition from the Preserve phase to the Consolidate phase of its strategic roadmap.
Generics GLP-1 Launch and CRDMO Growth
The Generics segment delivered Q4 EBITDA of Rs 75 crore at an 8% margin, improving approximately 300 basis points quarter on quarter, driven by generic Liraglutide sales in Europe. The Biocon Q4 results also included US FDA approval for generic Liraglutide covering both diabetes and weight management indications, opening a significant new revenue opportunity. Syngene reported Q4 operating revenue of Rs 1,037 crore at a 26% EBITDA margin.
Risks to Monitor
- Biosimilar pricing erosion: Entry of additional biosimilar competitors in the US for adalimumab and other key molecules could compress Biocon Q4 realisations in FY27.
- Integration execution risk: Fully integrating Biocon Biologics within the Biocon parent entity involves operational, regulatory, and governance complexity that could distract management.
- Debt reduction timeline: Elevated debt levels from the Biocon Biologics expansion require sustained cash generation for deleveraging, with any shortfall pressuring Biocon Q4 interest costs.
- Regulatory approval uncertainty: Delays in US FDA or EMA approvals for pipeline biosimilars could push out the revenue recognition timeline for key Biocon Q4 growth drivers.
Conclusion
The Biocon Q4 results FY26 confirm a company in the midst of a meaningful earnings recovery with Q4 PAT up 64% to Rs 179 crore and FY26 PAT up 323% to Rs 436 crore, driven by biosimilar scale-up and operating leverage. The Biocon Q4 integration of Biocon Biologics as a wholly-owned subsidiary is a landmark strategic move that simplifies the group structure.
For FY27, the most important variable for Biocon Q4 investors is whether the generic Liraglutide launch can scale quickly in both Europe and the US, and whether the biosimilars segment can sustain its 26% EBITDA margin as competition intensifies in the denosumab and adalimumab categories.
Download the Univest iOS App or Univest Android App for live Q4 results tracking and expert research.
Disclaimer: This article is for educational and informational purposes only and does not constitute investment advice. Univest analysts are SEBI-registered research analysts (SEBI RA: INH000012449). Investments in the securities market are subject to market risk. Consult a SEBI-registered financial advisor before making any investment decisions.
Frequently Asked Questions
What was the Biocon Q4 FY26 PAT?
Biocon Q4 FY26 net profit before exceptional items stood at Rs 179 crore, up 64% year on year on an adjusted basis excluding one-time generic Lenalidomide sales in Q4 FY25. EBITDA was Rs 1,073 crore at a 23% margin.
What is Biocon Q4 FY26 operating revenue?
Biocon Q4 FY26 consolidated operating revenue was Rs 4,517 crore, up 10% year on year on an adjusted basis. FY26 full year operating revenue reached Rs 16,927 crore, up 13% YoY on adjusted basis.
What is the Biocon FY26 dividend?
The Biocon Q4 FY26 board recommended a final dividend of Re 0.50 per equity share at 10% of face value for the financial year ended March 31, 2026, payable by August 31, 2026 subject to AGM approval on August 6, 2026.
What is the Biocon Biologics integration announcement?
The Biocon Q4 FY26 board approved the full integration of Biocon Biologics Limited as a wholly-owned subsidiary through a share swap involving up to 87.92 lakh Biocon shares at Rs 376.16 per share, creating a unified biopharmaceutical entity.
What drove Biocon Q4 FY26 PAT growth?
Biocon Q4 FY26 PAT growth of 64% was driven by Biosimilars EBITDA growing 33% to Rs 720 crore at a 26% margin, generic Liraglutide EU launch, Syngene operating efficiency, and the full-year benefit of the Biocon Biologics integration into consolidated accounts.
Recent Article
Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026
Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026
Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026
Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026
